Sonoma Pharmaceuticals (DB:O8Z) - Aandelenkoers, Nieuws & Analyse

O8Z Overzicht aandelen

O8Z fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 27.44% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €4M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Sonoma Pharmaceuticals, Inc. Concurrenten

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.6m

Apontis Pharma

XTRA:APPH

€80.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sonoma Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$4.09
52 Week Hoogtepunt	US$7.51
52 Week Laag	US$2.60
Bèta	1.38
11 maand verandering	0%
3 maanden verandering	-0.24%
1 Jaar Verandering	n/a
33 jaar verandering	-95.88%
5 jaar verandering	-96.14%
Verandering sinds IPO	-99.36%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	O8Z	DE Pharmaceuticals	DE Markt
7D	0%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe O8Z presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe O8Z presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is O8Z's price volatile compared to industry and market?
O8Z volatility
O8Z Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van O8Z is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van O8Z in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	10	Amy Trombly	sonomapharma.com

Sonoma Pharmaceuticals, Inc. ontwikkelt en produceert gestabiliseerd hypochlorigzuur (HOCl) producten voor wondverzorging, dierverzorging, oog- en neusverzorging, mondverzorging en dermatologische aandoeningen in de Verenigde Staten, Europa, Azië, Latijns-Amerika en internationaal. Het bedrijf biedt Lumacyn, een huidtoner; Regenacyn, een littekengel op recept; Reliefacyn voor het verlichten van rode bultjes, uitslag, oppervlakkige huidkloven, zonnebrand, vervelling en eczeem/atopische dermatitis; Gramaderm voor de behandeling van lokale milde tot matige acne; Epicyn, een antimicrobiële gezichtsreiniger; Levicyn, een HOCl-gebaseerd product op recept en vrij verkrijgbaar, dat wordt gebruikt om huidirritaties, rijtwonden, schaafwonden en brandwonden te verlichten; Celacyn, een gel om littekens te behandelen; SebuDerm om het branderige gevoel, de jeuk, het erytheem, de schilfering en de pijn die gepaard gaan met seborroïsch eczeem en seborroïsch eczeem te behandelen en te verlichten; en Pediacyn, een hydrogel voor atopische dermatitis. Het biedt ook Microcyn, een topische productlijn op basis van HOCl, ontworpen om een versnelde genezing te stimuleren door een reeks ziekteverwekkers aan te pakken; Ocucyn ooglid- en wimperreiniger; Ocudox voor oogverzorging; Sinudox voor neusspoeling; Microdacyn60 mondverzorgingsoplossing voor de behandeling van mond- en keelinfecties; en Podiacyn, een voetverzorgingsproduct.

Sonoma Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Sonoma Pharmaceuticals zich tot de beurswaarde?
O8Z fundamentele statistieken
Marktkapitalisatie	€3.39m
Inkomsten(TTM)	-€3.47m
Inkomsten(TTM)	€12.76m

0.3x

P/S-verhouding

-1.0x

Koers/Winstverhouding

Is O8Z overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
O8Z resultatenrekening (TTM)
Inkomsten	US$13.55m
Kosten van inkomsten	US$8.33m
Brutowinst	US$5.22m
Overige uitgaven	US$8.90m
Inkomsten	-US$3.69m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.75
Brutomarge	38.52%
Nettowinstmarge	-27.21%
Schuld/Eigen Vermogen Verhouding	1.5%

Hoe presteerde O8Z op de lange termijn?

Bekijk historische prestaties en vergelijking

O8Z Overzicht aandelen

Beloningen

Risicoanalyse

Sonoma Pharmaceuticals, Inc. Concurrenten

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.6m

XTRA:APPH

€80.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel

Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

Recent updates

Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel

Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

First quarter 2025 earnings released: US$0.067 loss per share (vs US$0.29 loss in 1Q 2024)

New major risk - Revenue and earnings growth

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Full year 2024 earnings released: US$0.53 loss per share (vs US$1.52 loss in FY 2023)

No longer forecast to breakeven

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings released: US$0.079 loss per share (vs US$0.62 loss in 3Q 2023)

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Insufficient new directors

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.81 loss in 3Q 2020)

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure